PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.12
−0.64%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.23
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.24
- EPS estimate
- -$0.26
- Revenue actual
- $1.2M
- Revenue estimate
- $2.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $7.00 – $9.00
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.26 | -$0.24 | Beat 6.70% | $1.2M |
| May 12, 2026 | -$0.24 | -$0.28 | Miss -16.67% | $856.0K |
| Mar 3, 2026 | -$0.25 | -$0.22 | Beat 12.00% | $838.0K |
| Nov 7, 2025 | -$0.28 | -$0.32 | Miss -14.29% | $1.2M |
| Aug 7, 2025 | -$0.36 | -$0.41 | Miss -13.89% | $1.1M |
| May 8, 2025 | -$0.32 | -$0.40 | Miss -25.00% | $1.5M |
| Feb 28, 2025 | -$0.37 | -$0.31 | Beat 16.22% | $2.2M |
| Aug 8, 2024 | -$0.40 | -$0.46 | Miss -15.00% | $37.8M |
| May 10, 2024 | -$0.45 | -$0.44 | Beat 2.22% | $591.0K |
| Mar 1, 2024 | -$0.48 | -$0.56 | Miss -16.67% | — |
| Nov 3, 2023 | -$0.45 | -$0.55 | Miss -22.22% | — |
| May 11, 2023 | -$0.42 | -$0.44 | Miss -4.76% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026